Related by context. All words. (Click for frequent words.) 79 CYT# potent vascular disrupting 77 lung pancreatic 76 kidney urologic 76 ovarian breast 75 metastatic gastric 75 pancreatic lung 75 LHRH receptor positive 75 Hepatocellular Carcinoma HCC 75 bladder ovarian 75 5 fluorouracil leucovorin 75 gefitinib Iressa 74 castration resistant hormone refractory 74 colorectal lung 74 metastatic pancreatic 74 pancreatic prostate 74 hormone refractory prostate 74 advanced metastatic renal 74 recurrent metastatic 74 Aflibercept 74 dasatinib Sprycel 74 recurrent NSCLC 73 erlotinib Tarceva ® 73 dasatinib Sprycel ® 73 metastatic androgen independent 73 pancreatic colon 73 receptor tyrosine kinase inhibitor 73 Sudhir Agrawal D.Phil 73 metastatic bladder 73 deCODE ProstateCancer TM 73 MAGE A3 ASCI 73 ovarian lung 73 colorectal bladder 73 vinca alkaloid 73 Combination REOLYSIN R 73 cell carcinoma RCC 73 non resectable metastatic 73 IgG1 monoclonal antibody 73 R Saizen R 73 gastrointestinal stromal 73 targeted radiotherapeutic 73 nonsmall cell lung cancer 73 ovarian pancreatic 72 Proxinium TM 72 unresectable tumors 72 GRNOPC1 contains 72 tumors GIST 72 Epidermal Growth Factor Receptor 72 metastatic malignant 72 myelofibrosis polycythemia vera 72 cisplatin resistant 72 essential thrombocythemia ET 72 R sorafenib tablets 72 recurrent glioblastoma multiforme 72 Vicinium TM 72 evaluating picoplatin 72 stage IIIb IV 72 chemosensitizer 72 antibody MAb 72 FUSILEV enhances 72 sorafenib tablets 72 ribonucleotide reductase clinically validated 72 nilotinib Tasigna ® 72 carcinoma HCC 72 protein tyrosine phosphatase 1B 72 hormone refractory metastatic prostate 72 resistant hormone refractory 72 metastatic GIST 72 intravesical infusion therapy 72 papillary renal cell carcinoma 72 nonmetastatic 72 metastatic carcinoma 72 BRCA deficient 72 systemic anaplastic large 72 ZACTIMA 72 pertuzumab 71 Patients Treated With 71 bladder cancers 71 ovarian endometrial 71 chimeric monoclonal antibody 71 myelodysplastic myeloproliferative diseases 71 evaluating T DM1 71 bevacizumab Avastin ® 71 Daclizumab 71 sunitinib Sutent 71 Enzastaurin 71 novel VDA molecule 71 Vidaza ® 71 gastrointestinal stromal tumors GISTs 71 pancreatic bladder 71 sorafenib Nexavar 71 colorectal ovarian 71 lymphomas leukemias 71 Nexavar sorafenib 71 metastatic renal 71 advanced unresectable 71 cetuximab Erbitux 71 castrate resistant prostate cancer 71 docetaxel Taxotere ® 71 receiving chemoradiation therapy 71 BCG refractory carcinoma 71 pain palliation 71 BRAF inhibitor 71 chronic myeloid 71 subependymal giant cell 71 Anthracycline 71 humanised monoclonal antibody 71 Irinotecan 71 accumulate preferentially 71 Hormone Refractory Prostate Cancer 71 advanced epithelial ovarian 71 adhesion molecule EpCAM expressing 71 radiofrequency ablation RFA 71 novel tubulin binding 71 Degarelix 71 catheter occlusion 71 familial amyloidotic polyneuropathy FAP 71 malignant ascites 71 Vandetanib 71 Prednisone Against Refractory 71 acid phosphatase PAP 71 unresectable locally advanced 71 prostate carcinoma 71 Immunotherapeutic 71 refractory metastatic 71 sarcoma melanoma 71 Factor Receptor 71 colorectal gastric 71 Pemetrexed 70 biliary tract cancer 70 colorectal pancreatic 70 epithelial tumors 70 gastrointestinal stromal tumors GIST 70 HER2 positive metastatic breast 70 chemotherapy cisplatin 70 fallopian tube cancers 70 Eculizumab 70 non squamous 70 Prolongs Survival 70 evaluating tivozanib 70 Temsirolimus 70 breast pancreatic 70 luteinizing hormone releasing 70 neuroendocrine cancers 70 vinca alkaloids 70 ovarian prostate 70 oral picoplatin 70 telomerase therapeutic 70 Papillary 70 epithelial ovarian 70 OMP #R# 70 endocrine therapies 70 gastro intestinal inflammation 70 Phase #b/#a clinical 70 imatinib Gleevec 70 metastatic castrate resistant 70 fallopian tube carcinoma 70 Zorbtive TM 70 assessing T DM1 70 alkylating agent 70 oncolytic virus therapies 70 PKC# 70 Squamous 70 thalidomide Thalomid 70 cyclophosphamide chemotherapy 70 cutaneous T 70 cediranib 70 Advanced Renal Cell 70 TNF Tumor Necrosis Factor 70 differentiated thyroid 70 Squamous Cell 70 mutated KRAS gene 70 aneurysms AAA 70 cervical breast 70 pancreatic colorectal 70 metastatic renal cell 70 candidates Azedra TM 70 Pertuzumab 70 gastrointestinal stromal tumor GIST 70 Basal Cell 70 Malignant Melanoma 70 Accelerated Partial Breast Irradiation 70 LymphoStat B belimumab 70 prostate carcinomas 70 prostate cancer HRPC 70 opioid induced constipation OIC 70 pan HDAC inhibitor 70 Bayer HealthCare Onyx Pharmaceuticals 70 pancreatic islet cell 70 gastric pancreatic 70 Ceflatonin 70 metaglidasen 70 multi kinase inhibitor 70 lenalidomide Revlimid R 70 Ixempra 70 unresectable liver cancer 70 Hsp# Inhibitor 70 hormone LHRH antagonist 70 Hepatocellular 70 imatinib Gleevec ® 70 metastatic colorectal carcinoma 70 gemcitabine chemotherapy 70 Cutaneous T 70 Surgical resection 70 metastatic HER2 positive 70 monoclonal antibody conjugated 70 Provectus Pharmaceuticals specializes 70 targeting miR 70 Folfox 70 irinotecan doxorubicin oxaliplatin paclitaxel 70 EOquin TM phase 70 Endometrial 70 acadesine 69 occlusion PAO 69 INSPIRE Trial Phase III 69 Selective Internal 69 EGFR TKI 69 delivers fluocinolone acetonide FA 69 Glioblastoma Multiforme 69 untreated metastatic pancreatic 69 #I TM# 69 ovarian colon 69 EGFR mutation positive 69 squamous non 69 acetonide FA 69 demonstrated antitumor activity 69 lexidronam injection 69 pancreatic gastric 69 MGd 69 Mitomycin C 69 Gliadel Wafer 69 GVAX ® 69 untreated metastatic melanoma 69 M2 subunit 69 relapsed MM 69 cetuximab Erbitux R 69 Cabazitaxel 69 ductal carcinomas 69 pancreatic carcinoma 69 pancreatic adenocarcinoma 69 radiation enteritis 69 thetreatment 69 colorectal carcinoma 69 situ CIS 69 AAG geldanamycin analog 69 anthracycline taxane 69 paclitaxel cisplatin 69 Fludara ® 69 prostate ovarian 69 HER2 amplified 69 Soft Tissue Sarcoma 69 refractory NSCLC 69 relapsed leukemia 69 trastuzumab Herceptin R 69 Temodar ® 69 interferon beta 1a infertility 69 metastatic castration resistant 69 Peginterferon alfa 2b 69 histone deacetylase HDAC inhibitor 69 hyperplasia BPH 69 Annamycin 69 bladder prostate 69 GW# [003] 69 BRAF mutant 69 metastatic renal cell carcinoma 69 VEGFR2 inhibitor 69 Azacitidine 69 triggers apoptosis programmed 69 HER1 69 hypereosinophilic syndrome 69 anastrazole 69 Epratuzumab 69 plus dacarbazine 69 delay bone metastases 69 brivanib 69 metastatic breast 69 CTAP# Capsules 69 KRAS mutant 69 Bevacizumab Avastin 69 docetaxel Taxotere R 69 iobenguane 69 lymphoid malignancies 69 refractory colorectal cancer 69 esophageal gastric 69 peritoneal carcinomatosis 69 alpha folate receptor 69 benign prostatic hyperplasia enlarged 69 oral Janus kinase 69 leukemia multiple myeloma 69 psoriasis rheumatoid arthritis 69 Her2 positive 69 IL# PE#QQR 69 pelvic malignancies 69 medically inoperable 69 Renal Cell Carcinoma 69 YONDELIS 69 Imetelstat 69 R lenalidomide 69 chronic thromboembolic pulmonary 69 Panzem 69 lung esophageal 69 ovarian bladder 69 Adjuvant Treatment 69 Achieves Primary Endpoint 69 modified glutathione analog 69 mertansine 69 MKC# MT 69 IAP inhibitor 69 recurrent metastatic ovarian cancer 68 molecule epidermal 68 ovarian esophageal 68 TTF Therapy 68 whose tumors overexpress 68 infectious diseases autoimmune diseases 68 microtubule inhibitor 68 adalimumab Humira 68 including eniluracil ADH 68 vinorelbine tartrate 68 paclitaxel Taxol 68 metastatic HER2 negative 68 basal cell carcinoma BCC 68 PNP inhibitor 68 Meets Primary Endpoint 68 Refractory Hodgkin Lymphoma 68 HER2 overexpression 68 castrate resistant 68 radiolabeled TM# 68 progressive metastatic prostate 68 TNFerade TM 68 unresectable stage 68 AKT inhibitor 68 ThermoDox R 68 FOLFOX6 68 ErbB2 positive 68 Interferon beta 68 Kinase Inhibitor 68 CDK cyclin dependent 68 hypervascular tumors 68 Apaziquone 68 metastatic ovarian cancer 68 recurrent squamous cell carcinoma 68 vaccine GRNVAC1 68 Xeloda ® 68 Squamous cell 68 indolent follicular non 68 CYT# vascular disrupting 68 selective angiogenic kinase inhibitor 68 erlotinib Tarceva 68 Platinol ® cisplatin 68 Darinaparsin 68 Ribavirin causes 68 cancer mCRC 68 CBLC# 68 immunotherapeutic agent 68 untreated metastatic colorectal 68 Crizotinib 68 PSMA ADC 68 pancreatic ovarian 68 mapatumumab 68 pan histone deacetylase 68 aflibercept VEGF Trap 68 pancreas esophagus 68 taxane chemotherapy administered 68 colorectal liver 68 5 FU leucovorin 68 Gleevec resistant 68 huC# DM4 68 Relapsed Refractory 68 Gemzar gemcitabine 68 complement inhibitor eculizumab 68 Panzem NCD 68 metastatic liver 68 AEG# 68 mTOR mammalian target 68 metastatic neuroendocrine tumors 68 induced mucositis 68 gastrointestinal mucositis 68 Velcade bortezomib 68 Basal cell 68 Mg Usa 68 PEGylated Fab fragment 68 Aplidin 68 secretory phospholipase A2 68 leukemia AML 68 acute peripheral arterial 68 Taxol ® 68 radiotherapeutic 68 stage IIIB 68 sunitinib Sutent ® 68 Xelox 68 sirtuin inhibitor program 68 ® lenalidomide 68 arthritis PsA 68 recurrent glioblastoma multiforme GBM 68 Afatinib 68 refractory indolent non 68 anti angiogenic agent 68 metastatic hormone refractory 68 liposomal doxorubicin 68 IGF IR 68 5 HT4 68 Kit CD# positive 68 treat benign prostatic 68 taxane refractory 68 gastrointestinal stromal tumors 68 chronic eosinophilic leukemia 68 colon pancreas 68 skeletal metastases 68 gemcitabine carboplatin 68 docetaxel Taxotere 68 refractory chronic lymphocytic 68 pediatric malignancies 68 Adjuvant chemotherapy 68 keloid scarring 68 alkylating 68 Epothilone D 68 Phase 2b Clinical Trial 68 doublet chemotherapy 68 induced macular edema 68 Factor VIIa 68 trastuzumab DM1 68 superficial basal cell carcinoma 68 lung ovarian 68 Deforolimus 68 Xanafide 68 sodium thiosulfate STS 68 proteasome inhibitor 68 HGS ETR1 mapatumumab 68 prostate cancer antigen prostatic 68 benign neoplasms 68 Vidaza R 68 allogeneic HSCT 68 Methylnaltrexone 68 breast endometrial 68 gastrointestinal stromal tumor 68 Anti VEGF 68 atypical Hemolytic Uremic Syndrome 68 cisplatin gemcitabine 68 neoadjuvant therapy 68 relapsing remitting MS RRMS 68 Cloretazine R 68 Philadelphia Chromosome Positive 68 EGFR expressing 68 Antitumor Activity 68 Romidepsin 68 PLX MS 68 Navelbine ® 68 HDAC Inhibitor 68 constipation OIC 68 advanced hepatocellular carcinoma 68 poly ADP ribose polymerase 68 oral prodrug 68 orally administered inhibitor 68 5 HT2A serotonin 68 Telik logo TELINTRA 68 IMA# 68 pulmonary metastases 68 VANTAS ® 68 AA Amyloidosis 68 Tyrosine Kinase Inhibitors 68 malignant pleural mesothelioma 68 prostate colon 68 chemoradiation therapy 68 Omacetaxine 68 nilotinib Tasigna 68 Leukemias 68 Phase 1b clinical trials 68 radiation chemoradiation 68 abnormal p# 68 pralatrexate injection folate analogue 68 K ras mutations 68 cutaneous T cell 68 Ph + acute lymphoblastic 68 OMP #M# 68 cell lymphoma CTCL 68 breast ovary 68 anti PlGF 68 Amrubicin 68 OncoVex 67 lung malignant melanoma 67 ® bevacizumab 67 Plaquenil 67 Bosutinib 67 Personalized Immunotherapy 67 ZACTIMA TM ZD# 67 Paraplatin ® 67 VALSTAR TM 67 mRCC 67 Vitrasert R 67 ixabepilone 67 advanced HER2 positive 67 alpha1 antitrypsin deficiency 67 leukemias lymphomas 67 invasive lobular 67 trastuzumab Herceptin ® 67 Dasatinib 67 denileukin diftitox 67 MEK Inhibitor 67 Sapacitabine 67 antiangiogenic therapy 67 humanized therapeutic 67 mTOR inhibitors 67 Curaxin CBLC# 67 liver colon rectal 67 irinotecan chemotherapy 67 lung ovary 67 Exherin TM 67 transthyretin TTR mediated amyloidosis 67 Troxatyl 67 completely resected 67 Intravitreal 67 Hodgkin lymphoma HL 67 Naive Patients 67 CTAP# 67 castration resistant 67 Myelodysplastic Syndrome MDS 67 Cannabinor 67 Novel Oral 67 ospemifene 67 hypoxia activated prodrug 67 Bayer Nexavar 67 surgically resectable 67 p# biomarker 67 CCR9 antagonist 67 RhuDex R 67 Clolar ® 67 basal cell skin 67 Vidaza azacitidine 67 MCSP respectively 67 Carcinoid tumors 67 taxane resistant 67 Trabectedin 67 IMiDs ® 67 Gefitinib 67 Gemzar ® 67 HER2 positive cancers 67 MAGE A3 67 Initiates Enrollment 67 Ozarelix 67 Nexavar tablets 67 myocardial infarction ventricular fibrillation 67 HER2 positive breast 67 paclitaxel Taxol R 67 Tesmilifene 67 androgen independent 67 Randomized Phase II 67 Romiplostim 67 rheumatoid arthritis RA psoriatic 67 Everolimus 67 soluble tumor necrosis 67 estramustine 67 histone deacetylase inhibitor 67 secondary hyperparathyroidism 67 Camptosar ® 67 multiple myeloma MM 67 Lilly Gemzar 67 refractory prostate cancer 67 basiliximab 67 carcinoma mCRC 67 Panzem R 67 selectively inhibited 67 monoclonal antibody IgG1 Mab 67 Endologix Powerlink System 67 fosbretabulin 67 Tarceva TM 67 targeted antifolate 67 Neoadjuvant 67 ELACYT 67 Colon polyps 67 endometrial breast 67 stage chemoresistant ovarian 67 melanoma ovarian 67 novel immunotherapies 67 Aliskiren 67 seminoma 67 antibody MT# 67 bladder cervix 67 Chronic Myelogenous Leukemia CML 67 Ovitrelle R Serostim 67 albiglutide currently 67 GRN# 67 bortezomib Velcade 67 Intravenous CP 67 Zybrestat 67 MKC# MKC# PP 67 investigational monoclonal antibody 67 Cloretazine ® 67 ovarian cervical 67 Bezielle 67 concurrent chemoradiation 67 lintuzumab SGN 67 Aurora Kinase 67 antiangiogenesis therapies 67 PARP inhibitor 67 vapreotide acetate 67 NeoLipid R 67 selective modulator 67 hepatocellular cancer 67 superficial bladder cancer 67 potent inducer 67 Erbitux cetuximab 67 BRIM2 67 Fludarabine 67 basal cell carcinoma squamous 67 included exfoliative dermatitis 67 EGFR mutant 67 pediatric acute lymphoblastic 67 potent antiproliferative 67 anthracycline chemotherapy 67 non hodgkin lymphoma 67 brand ciclesonide HFA 67 alvespimycin 67 galiximab 67 GSTP1 67 BRAF mutated 67 Angiotensin Converting Enzyme 67 Solazed TM 67 overactive bladder VANTAS R 67 Androgen deprivation therapy 67 cardio metabolic diseases 67 KRAS oncogene 67 Syndrome LEMS 67 LymphoStat B TM 67 antibody trastuzumab 67 AVASTIN 67 investigational immunotherapy 67 refractory gastrointestinal stromal 67 ovary uterus 67 Thiarabine 67 PI3K/Akt pathway inhibitor 67 small molecule tyrosine 67 efaproxiral 67 prostate cancer mCRPC 67 selective kinase inhibitor 67 advanced pancreatic neuroendocrine 67 novel antimitotic agent 67 BCG refractory 67 ALN HPN 67 Fluorouracil 67 ACTEMRA TM 67 EGFR tyrosine kinase inhibitor 67 Radiation Therapy SIRT 67 neovascular diseases 67 Completes Patient Enrollment 67 TOCOSOL Camptothecin 67 dependent kinase inhibitor 67 pathophysiological effects 67 underwent surgical resection 67 trial evaluating PRX# 67 Allovectin 7 67 EGFR HER2 67 refractory metastatic colorectal cancer 67 Smac mimetics 67 multiple sclerosis psoriasis 67 oral clodronate 67 Glioblastoma Multiforme GBM 67 tiuxetan 67 treating sarcoma testicular 67 inhibit EGFR 67 IMiDs ® compound 67 oral dihydropyrimidine dehydrogenase DPD 67 HCV NS5B polymerase 67 grade cervical intraepithelial 67 Talabostat 67 HER2 ErbB2 67 NAVISTAR R 67 Cell Lymphoma CTCL 66 DG# compounds targeting 66 mTOR inhibitor 66 leukemia myeloma 66 Vidofludimus 66 antiangiogenesis 66 intraoperative radiotherapy 66 Torisel temsirolimus 66 endometrial hyperplasia 66 taxane chemotherapy 66 Diffuse Large B 66 CYP#A# CYP#D# 66 agonistic human 66 plus gemcitabine 66 substantially excreted 66 pancreas colon 66 EGFr 66 Taxotere docetaxel 66 esophageal candidiasis 66 radiation sensitizer 66 SPRYCEL ® 66 Prodarsan R 66 Bevacizumab 66 etanercept Enbrel 66 FOLFOX chemotherapy 66 commercialize deforolimus 66 minimally symptomatic 66 Nexavar ® 66 Obatoclax 66 generation purine nucleoside 66 follicular Non Hodgkin 66 aerosolized AAT 66 Safinamide 66 adriamycin 66 endoluminal stent graft 66 diarrhea predominant irritable 66 Lymphocytic 66 Study Evaluating 66 5 Fluorouracil 66 refractory acute myeloid 66 tumor angiogenesis inhibitors 66 transarterial 66 Trastuzumab DM1 66 PF # [002] 66 Taxanes 66 colon ovarian 66 Darapladib 66 specific lectin receptors 66 Monoclonal antibody 66 Zolinza 66 Oxaliplatin 66 histone deacetylase HDAC inhibitors 66 HuMax EGFr 66 pulmonary metastasis 66 ergot derivatives 66 dysplastic lesions caused 66 Rituxan rituximab 66 cause mesothelioma asbestosis 66 recurrent epithelial ovarian 66 rheumatoid arthritis psoriatic arthritis 66 Cloretazine 66 Shows Promise Against 66 signal transduction inhibitors 66 benign prostatic hypertrophy BPH 66 Sorafenib 66 SUPPRELIN R LA 66 urothelial carcinoma 66 IV Busulfex 66 gemcitabine Gemzar ® 66 membranous nephritis 66 nucleoside analog 66 Onconase 66 Archexin 66 antiestrogen 66 Trial Evaluating 66 hormonally sensitive 66 TNFerade ™ 66 deep venous thromboses 66 bevacizumab Avastin R 66 ZOLINZA 66 TTR amyloidosis 66 Complicated Skin 66 bevacizumab Avastin 66 TNF Blockers 66 osteolytic bone disease 66 angiogenesis inhibitor 66 Malignant Glioma 66 bone marrow reticulin deposition 66 Golimumab 66 Quinamed 66 transthyretin amyloidosis 66 treating cancerous tumors 66 intravesical instillation 66 SNT-MC#/idebenone 66 biliary cancer 66 Ophena TM 66 RNAi therapeutic targeting 66 Erlotinib 66 Locked Nucleic Acid LNA 66 humanised antibody 66 recurrent glioblastoma 66 reduce serum phosphate 66 ovarian carcinoma 66 ATC ovarian cancer 66 polycythemia vera PV 66 Vincristine 66 vitreoretinal disorders 66 ALN PCS 66 recurrent glioma 66 depsipeptide 66 prokinetic agent 66 haematologic 66 biologic antibody 66 Novartis Afinitor 66 Arimidex anastrozole 66 infliximab Remicade 66 Orally administered 66 Syncria R 66 pegylated liposomal doxorubicin 66 Oral Fingolimod 66 BRCA1 BRCA2 66 Silodosin 66 chronically immunosuppressed solid 66 hypermethylated 66 autologous cellular immunotherapy 66 CLL SLL 66 chemo resistant 66 approved incretin mimetic 66 colorectal breast 66 Mg Uk 66 non porcine pancreatic 66 paclitaxel Taxol ® 66 TNF alpha selectively neutralizing 66 aripiprazole Abilify 66 aurora kinase 66 advanced medullary thyroid 66 Pivotal Phase III 66 Glufosfamide 66 midstage clinical 66 cetuximab Erbitux ® 66 non resectable 66 Certolizumab pegol 66 oropharyngeal candidiasis OPC 66 ALK inhibitors 66 stage IIIB IV 66 CYP#A# substrate 66 undergoing hematopoietic stem 66 Femara letrozole 66 HQK 66 non mutated KRAS 66 Intravenous immunoglobulin 66 lymphoma CTCL 66 beta 1a 66 Metastatic 66 premalignant lesion 66 regorafenib 66 Hycamtin ® 66 Pruvel TM 66 cyclophosphamide methotrexate 66 Mitoxantrone 66 Squalamine 66 Metastatic Prostate Cancer 66 resectable 66 Teverelix 66 T#I [002] 66 PEG SN# 66 Patients Receiving 66 investigational humanized monoclonal antibody 66 mitoxantrone plus 66 intrahepatic bile duct 66 oral dual endothelin 66 Tanespimycin 66 refractory cutaneous T 66 B Cell Lymphoma 66 Cetuximab Erbitux 66 Improves Outcomes 66 hematological diseases 66 Lupus Nephritis 66 induce apoptosis programmed 66 hematopoietic disorders 66 SCCHN 66 oral ghrelin agonist 66 Peptide YY 66 vaginal candidiasis 66 Gleevec imatinib mesylate 66 doxorubicin Adriamycin 66 Cytotoxic 66 urothelial cancer 66 Known hypersensitivity 66 nasopharyngeal carcinoma 66 antiproliferative effects 66 mutated K ras 66 trastuzumab DM1 T DM1 66 methylnaltrexone bromide 66 Sezary syndrome 66 LRP5 66 cilengitide 66 adjuvant GIST 66 YONDELIS R 66 corticosteroid dexamethasone 66 visilizumab 66 AERx ® 66 gastroesophageal junction 66 novel therapeutic antibodies 66 immuno modulatory 66 RhuDex ® 66 advanced metastatic prostate 66 humanized monoclonal antibodies 66 prostate cancer AIPC 66 HepDirect prodrug 66 carmustine 66 CD# CEA 66 IRX 2 66 KRAS mutations occur 66 R vitespen 66 Curaxin 66 anaplastic lymphoma kinase ALK 66 finasteride Proscar 66 treat enlarged prostate 66 Tocilizumab 66 3 registrational trial 66 multitargeted 66 NMIBC 66 Recombinant interferon alpha 66 relapsed ovarian cancer 66 anti angiogenic agents 66 Genasense ® oblimersen 66 cisplatin chemotherapy 66 Lilly Alimta 66 Atypical Hemolytic Uremic Syndrome 66 advanced carcinoid 66 IMiDs R 66 Onalta TM 66 neovasculature 66 cholangiocarcinoma 66 Myocet 66 PLX STROKE targeting 66 antimitotic 66 Adjuvant Chemotherapy 66 testicular cancers 66 Campath alemtuzumab 66 idarubicin 66 cirrhosis liver failure 66 Initiates Clinical Trial 66 hepatocellular carcinoma HCC 66 Metastatic breast cancer 66 aldehyde dehydrogenase ALDH2 deficiency 66 androgen dependent 66 NASH Huntington 66 MEK inhibitor 66 systemic ALCL 66 Sutent sunitinib 66 apoptosis proteins 65 Gastric Cancer 65 gemcitabine cisplatin 65 NU# direct 65 Initiate Clinical Trial 65 Neuvenge 65 interferon gamma 1b 65 potent suppressor 65 novel histone deacetylase 65 hormone LHRH 65 toenail onychomycosis 65 Zalypsis 65 Hedgehog Pathway Inhibitor 65 neuroendocrine carcinoma 65 breast carcinomas 65 IMiDs 65 malignant ovarian 65 Zarnestra 65 leukemia lymphomas 65 nodal metastasis 65 Pathway Inhibitor 65 Bisphosphonate 65 Cancer Incidence Mortality 65 HuLuc# 65 immunodeficiency disorders 65 demethylating agent 65 follicular lymphoma FL 65 Acute Exacerbations 65 Brentuximab Vedotin SGN 65 squamous cell carcinoma SCC 65 Roche Herceptin 65 microsphere therapy 65 chemoradiotherapy 65 Xeloda capecitabine 65 FOLFOX6 chemotherapy regimen 65 budesonide foam 65 lung colorectal 65 TKB# 65 RANK Ligand inhibitor 65 prostate pancreatic 65 hormone receptor negative 65 irreversible inhibitor 65 temsirolimus 65 Tyrima 65 postoperative pathology 65 Stereotactic Body Radiation Therapy 65 TO AVOID PREGNANCY WHILE 65 unresectable recurrent 65 Acute myelogenous leukemia 65 antimetabolite 65 interstitial cystitis IC 65 pheochromocytoma 65 xanthine oxidase inhibitor 65 transplantation HCT 65 cervical carcinoma 65 topically administered 65 Bucindolol 65 T1c 65 GISTs 65 Dupuytren Disease 65 renal cell carcinomas 65 relapsed refractory multiple myeloma 65 Preclinical Models 65 D aspartate NMDA receptor 65 ToGA 65 oncologic diseases 65 topically applied SEPA 65 Warfarin Coumadin 65 hyperphenylalaninemia HPA due 65 FUSILEV ® 65 EGFr expressing metastatic colorectal 65 syngeneic 65 Eluting Stent 65 AGTR1 65 Shark cartilage 65 Dendreon investigational 65 squamous cell lung cancer 65 irinotecan oxaliplatin 65 Cotara ® 65 Torisel 65 estrogen receptor beta agonist 65 Belimumab